Adhiraj Singh Chauhan

Reporting to: General Director, Vice President.

Team Size: 4 direct reports.

• Built and scaled a $50 million+ cross-border alliance portfolio.
• Spearheaded licensing, divestment, and BD projects, aligning regional interests with global M&A.
• Represented Asia in global forums, aligning regional goals with regional performance.
• Executed a strategic 5-year plan for Asia.
• Cultivated future leaders through targeted mentoring initiatives.

• Delivered a 14% CAGR over 5 years, with full P&L ownership.
• Secured partnerships with health agencies and NGOs for Hepatitis B and C programs.
• Negotiated in-licensing, distribution, and co-marketing deals to expand the portfolio.
• Established effective KAM frameworks, resulting in a 37% CAGR growth in private healthcare facilities.
• Enhanced brand equity by implementing educational and training programs for pharmacy chains.
• Launched the Wholesaler Partnership Program to enhance geographic expansion.

Business Development Highlights at Viatris

• Facilitated geographic expansion of the Idorsia partnership, enhancing pipeline access across Southeast Asia.
• Regional Distribution Agreement with ZPV.
• Collaborative Sales Agreement with Cooper Consumer for the region.
• Enhanced Southeast Asia presence through Medochemie tech-transfer partnership in Vietnam.
• Key contributor to global deal teams for strategic divestment's in biosimilars, APIs, and women’s health.
• Led a voluntary licensing deal for infectious disease with Gilead.

• Launched operations for Mylan in the SAARC nations.
• Implemented access-driven portfolio strategies, resulting in USD 7M+ revenue generation.
• Developed local partnerships for effective launch of Biosimilars and Hepatitis treatments.

• Implemented a 5-year strategic growth plan, resulting in a 26% CAGR across GCC and Levant markets.
• Generated USD 8M in revenue through adaptive distributor strategies and robust operational plans.

• Achieved growth by driving advancements within India's largest biopharmaceutical company.
• Increased regional sales of small molecule APIs and tech transfer deals, achieving business growth to USD 34 million.
• Optimized BD activities across biological products, insulins, and immunosuppressants. Secured USD 8.25 million by implementing varied turnkey projects internationally (Turkey, Egypt, and Iran).